在强诱导剂卡马西平存在的情况下，每日一次含多替替韦方案持续抑制病毒。

IF 1.3 4区医学 Q4 INFECTIOUS DISEASES

Antiviral Therapy Pub Date : 2025-04-01 Epub Date: 2025-04-14 DOI:10.1177/13596535251335080

Micol Pallanza, Paul Thoueille, Myriam Briki, Susana Alves Saldanha, Matthias Cavassini, Catia Marzolini

{"title":"在强诱导剂卡马西平存在的情况下，每日一次含多替替韦方案持续抑制病毒。","authors":"Micol Pallanza, Paul Thoueille, Myriam Briki, Susana Alves Saldanha, Matthias Cavassini, Catia Marzolini","doi":"10.1177/13596535251335080","DOIUrl":null,"url":null,"abstract":"Dolutegravir 50 mg twice daily (BID) dosing is currently recommended in presence of strong inducers of drug metabolism. However, this dosing has been challenged by studies showing similar rates of viral suppression with dolutegravir once daily (QD) compared to BID dosing in presence of the strong inducer rifampicin. We report the case of a 41-year-old man with sustained virological suppression and documented therapeutic dolutegravir concentration on once daily dosing while treated with the strong inducer carbamazepine. Therapeutic drug monitoring can guide the need for twice daily dosing dolutegravir in presence of strong inducers.","PeriodicalId":8364,"journal":{"name":"Antiviral Therapy","volume":"30 2","pages":"13596535251335080"},"PeriodicalIF":1.3000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Sustained viral suppression with once daily dolutegravir-containing regimen in presence of the strong inducer carbamazepine.\",\"authors\":\"Micol Pallanza, Paul Thoueille, Myriam Briki, Susana Alves Saldanha, Matthias Cavassini, Catia Marzolini\",\"doi\":\"10.1177/13596535251335080\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Dolutegravir 50 mg twice daily (BID) dosing is currently recommended in presence of strong inducers of drug metabolism. However, this dosing has been challenged by studies showing similar rates of viral suppression with dolutegravir once daily (QD) compared to BID dosing in presence of the strong inducer rifampicin. We report the case of a 41-year-old man with sustained virological suppression and documented therapeutic dolutegravir concentration on once daily dosing while treated with the strong inducer carbamazepine. Therapeutic drug monitoring can guide the need for twice daily dosing dolutegravir in presence of strong inducers.\",\"PeriodicalId\":8364,\"journal\":{\"name\":\"Antiviral Therapy\",\"volume\":\"30 2\",\"pages\":\"13596535251335080\"},\"PeriodicalIF\":1.3000,\"publicationDate\":\"2025-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Antiviral Therapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/13596535251335080\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/4/14 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q4\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Antiviral Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/13596535251335080","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/14 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

摘要

多替格拉韦50mg，每日两次（BID）剂量目前推荐存在强药物代谢诱导剂。然而，这种剂量受到了一些研究的挑战，这些研究显示，在存在强诱导剂利福平的情况下，与BID剂量相比，每天一次的多替格拉韦（QD）对病毒的抑制率相似。我们报告一例41岁男性持续病毒学抑制和记录治疗多替格拉韦浓度每日一次剂量，同时与强诱导剂卡马西平治疗。治疗药物监测可以指导在存在强诱导剂的情况下每天两次给药多替格拉韦的需要。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Sustained viral suppression with once daily dolutegravir-containing regimen in presence of the strong inducer carbamazepine.

Dolutegravir 50 mg twice daily (BID) dosing is currently recommended in presence of strong inducers of drug metabolism. However, this dosing has been challenged by studies showing similar rates of viral suppression with dolutegravir once daily (QD) compared to BID dosing in presence of the strong inducer rifampicin. We report the case of a 41-year-old man with sustained virological suppression and documented therapeutic dolutegravir concentration on once daily dosing while treated with the strong inducer carbamazepine. Therapeutic drug monitoring can guide the need for twice daily dosing dolutegravir in presence of strong inducers.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Antiviral Therapy 医学-病毒学

CiteScore

2.60

自引率

8.30%

发文量

审稿时长

4-8 weeks

期刊介绍： Antiviral Therapy (an official publication of the International Society of Antiviral Research) is an international, peer-reviewed journal devoted to publishing articles on the clinical development and use of antiviral agents and vaccines, and the treatment of all viral diseases. Antiviral Therapy is one of the leading journals in virology and infectious diseases. The journal is comprehensive, and publishes articles concerning all clinical aspects of antiviral therapy. It features editorials, original research papers, specially commissioned review articles, letters and book reviews. The journal is aimed at physicians and specialists interested in clinical and basic research.